NCAPH and neoplasm: Combining NCAPH-KD with an mTOR inhibitor (Everolimus, Eve) or a cyclin-dependent kinase inhibitor (Flavopiridol, Flav) shows a promising anti-tumor effect in PCa cells both in vitro and in vivo.